Brief: OSE Immunotherapeutics Provides 2024 Outlook

Ose Immunotherapeutics SA

19/01/2024 06:39

Jan 19 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS HIGHLIGHTS CLINICAL PORTFOLIO
ADVANCEMENTS AND PROVIDES 2024 OUTLOOK
    * BOTH DOSSIERS HAVE JUST RECEIVED A POSITIVE REVIEW FROM
AMERICAN
AGENCY THAT SHOULD ENABLE TRIAL INITIATION IN US IN Q2 2024, AND
EXTENSION TO EUROPE IN S2 2024
    * TEDOPI®, OPTIMIZED EPITOPE-BASED CANCER: VACCINE DOSSIER
AND
PROTOCOL APPROVED BY FDA (FOOD AND DRUG ADMINISTRATION) IN
MID-JANUARY TO LAUNCH A NEW CONFIRMATORY PHASE 3 CLINICAL TRIAL
IN SECOND-LINE LUNG CANCER
    * PANCREATIC CANCER: RESULTS EXPECTED IN 2024
    * OVARIAN CANCER: RESULTS EXPECTED IN 2025
    * IN LUNG CANCER: RESULTS EXPECTED IN 2025, IN COMBINATION
WITH AN
ANTI-PDA, NIVOLUMAB
    * OSE-127/LUSVERTIKIMAB: ANTI-IL-7 RECEPTOR MONOCLONAL
ANTIBODYPHASE 2 CLINICAL TRIAL ONGOING IN ULCERATIVE COLITIS;
END OF PATIENT ENROLLMENT EXPECTED IN Q1 2024
    * FIRST RESULTS (FROM INDUCTION TO WEEK 10 AND AFTER 6
MONTHS OF
MAINTENANCE) ARE EXPECTED IN MID-2024
    * LUSVERTIKIMAB: END OF RECRUITMENT IS NOW EXPECTED IN Q1
2024
    * OSE-279: PROPRIETARY ANTI-PD1PHASE 1/2 CLINICAL TRIAL
ONGOING IN
SOLID TUMORS
    * OSE-279: UPDATED PRESENTATION OF THESE RESULTS IS PLANNED
FOR
END OF FEBRUARY 2024
    * OSE-279:  FROM Q1 2024, THE COMPANY COULD HAVE VALIDATED
DOSES
AND THERAPEUTIC REGIMENS TO CONSIDER THE IMPLEMENTATION OF
POSSIBLE OTHER CLINICAL TRIALS
    * FR104/VEL-101: TWO CLINICAL TRIALS, A PHASE 1/2 AND A
PHASE 1,
COMPLETED IN 2023 – RESULTS EXPECTED IN 2024
    * FR104/VEL-101: VELOXIS PLANS TO CONTINUE DEVELOPING THE
PRODUCT
SUBCUTANEOUSLY IN AN INTERNATIONAL PHASE 2 STUDY IN KIDNEY
TRANSPLANTATION

Source text for Eikon:  ID:nBw2vMXSqa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))